These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7320607)

  • 21. [Algorithm for the differential diagnosis of hyperlipidemia].
    Szemraj E; Leowski J; Tatoń J
    Pol Tyg Lek; 1985 Dec; 40(50):1415-8. PubMed ID: 3831991
    [No Abstract]   [Full Text] [Related]  

  • 22. [Plasma apolipoproteins in dyslipoproteinemias. III. Classical hyperlipemias].
    Duclos P; Davignon J
    Union Med Can; 1978 Mar; 107(3):264-9. PubMed ID: 636109
    [No Abstract]   [Full Text] [Related]  

  • 23. [Serum apo A-IV concentration in patients with hyperlipidemia].
    Seishima M; Maeda S; Yamashiro M; Abe A; Kawade M; Muto Y
    Rinsho Byori; 1988 Jan; 36(1):83-7. PubMed ID: 3367524
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of apolipoprotein E gene plasma levels of lipids, lipoproteins, apolipoproteins and its relation with coronary heart disease].
    Zhu T; Wang Z; Zhao S
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):149-51. PubMed ID: 10681829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Symposium on hyperlipidemia--epidemiological, clinical and experimental studies. Phospholipids and their fatty acid composition in hyperlipemia (author's transl)].
    Yamamoto A
    Nihon Naika Gakkai Zasshi; 1974 Oct; 63(10):1155-9. PubMed ID: 4474333
    [No Abstract]   [Full Text] [Related]  

  • 26. [Symposium on hyperlipidemia--epidemiological, clinical and experimental studies. Plasma lipoprotein metabolism and lecithin: cholesterol acyltransferase (author's transl)].
    Akanuma Y
    Nihon Naika Gakkai Zasshi; 1974 Oct; 63(10):1149-54. PubMed ID: 4474332
    [No Abstract]   [Full Text] [Related]  

  • 27. [On the etiology of diabetic hyperlipidemia from the aspects of the metabolism of ApoHDL (author's transl)].
    Keimatsu M
    Hokkaido Igaku Zasshi; 1981 Sep; 56(5):557-69. PubMed ID: 7319464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E phenotypes and serum lipid levels in apparently healthy male adults in Tokyo.
    Tsuchiya S; Yamanouchi Y; Miyazaki R; Onuki M; Yamakawa K; Kondo I; Ohnuki M; Hamaguchi H
    Jinrui Idengaku Zasshi; 1986 Mar; 31(1):15-20. PubMed ID: 3735754
    [No Abstract]   [Full Text] [Related]  

  • 29. [Xanthoma and atherosclerosis in the presence of normal plasma lipids].
    Davignon J; Bouthillier D; Dufour R; Lussier-Cacan S
    Ann Med Interne (Paris); 1983; 134(5):483-91. PubMed ID: 6651070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperlipidemia and atherosclerosis in Switzerland. Results from the "Basler studie" (author's transl)].
    Hartmann G; Stähelin HB
    Ther Umsch; 1980 Nov; 37(11):980-4. PubMed ID: 7455963
    [No Abstract]   [Full Text] [Related]  

  • 31. [Isolation of apolipoproteins A-I, A-II and E and their estimation by rocket immunoelectrophoresis in blood plasma of dis-alpha-lipoproteinemic patients].
    Klimov AN; Usatenko MS; Denisenko AD; Kozhevnikova KA; Oleĩnik IA
    Biokhimiia; 1981 Apr; 46(4):590-602. PubMed ID: 6793091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperlipidaemia and cardiovascular disease: apolipoprotein measurements and metabolic syndrome as predictors of cardiovascular risk.
    Deans KA; Dominiczak MH
    Curr Opin Lipidol; 2008 Dec; 19(6):624-6. PubMed ID: 18957887
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hyperlipidemia and blood alcohol determination (author's transl)].
    Brettel HF
    Z Rechtsmed; 1974 Jun; 74(3):181-5. PubMed ID: 4848892
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical applications and standardization of apolipoprotein measurements in the diagnostic workup of lipid disorders.
    Cooper GR; Henderson LO; Smith SJ; Hannon WH
    Clin Chem; 1991 May; 37(5):619-20. PubMed ID: 2032313
    [No Abstract]   [Full Text] [Related]  

  • 35. [Serum vitamin E levels in various diseases--mainly in hyperlipemia (author's transl)].
    Shimizu Y; Kibata M
    Nihon Ronen Igakkai Zasshi; 1978 Sep; 15(5):463-70. PubMed ID: 713158
    [No Abstract]   [Full Text] [Related]  

  • 36. [Multitesting health screening in Fukuoka City. 2) Serum glycosaminoglycans in health and diseases (author's transl)].
    Hasegaua O; Kimura K; Hirota T; Takasugi M; Ibayashi H
    Nihon Ronen Igakkai Zasshi; 1978 May; 15(3):245-50. PubMed ID: 671826
    [No Abstract]   [Full Text] [Related]  

  • 37. [Plasma apolipoprotein E levels in hyperlipidemia (author's transl)].
    Yamada N; Murase T; Akanuma Y; Kosaka K
    Nihon Naika Gakkai Zasshi; 1981 Sep; 70(9):1249-53. PubMed ID: 7320607
    [No Abstract]   [Full Text] [Related]  

  • 38. The influence of apoprotein epsilon 2 homozygosity on nephrotic hyperlipidemia.
    Joven J; Vilella E
    Clin Nephrol; 1997 Sep; 48(3):141-5. PubMed ID: 9342484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risks for hyperlipidemia.
    Nestruck AC; Davignon J
    Cardiol Clin; 1986 Feb; 4(1):47-56. PubMed ID: 2871933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Disorders of lipid metabolism assessed by the changes in the plasma concentrations of apolipoproteins (author's transl)].
    Koga S
    Nihon Naika Gakkai Zasshi; 1980 Oct; 69(10):1239-41. PubMed ID: 7462752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.